- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06571045
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)
Une étude pivot de phase 2/3, randomisée, à double insu, multicentrique, à 3 bras, pour évaluer l'efficacité et l'innocuité de l'EYE103 intravitréen par rapport au ranibizumab intravitréen (0,5 mg) chez des participants souffrant d'œdème maculaire diabétique
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Frankfurt, Allemagne, 60590
- Frankfurt, Germany
-
Hanover, Allemagne, 30625
- Hanover, Germany
-
München, Allemagne, 80336
- Munchen, Germany
-
Münster, Allemagne, 48145
- Munster, Germany
-
-
-
-
-
CABA, Argentine, 1023
- Buenos Aires, Argentina
-
Córdoba, Argentine, X5000AAJ
- Ciudad de Cordoba, Argentina
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentine, 1015
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentine, 1120
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentine, C1033AAW
- Buenos Aires, Argentina
-
Caba, Buenos Aires, Argentine, C1116ABA
- Caba, Buenos Aires, Argentina
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentine, 5000
- Cordoba, Argentina
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentine, S2000DSK
- Santa Fe, Argentina
-
-
Sante Fe
-
Rosario, Sante Fe, Argentine, 2000
- Santa Fe, Argentina
-
-
-
-
-
Albury, Australie, 2640
- Albury, Australia
-
Parramatta, Australie, 2150
- Parramatta, Australia
-
Sydney, Australie, 2000
- Sydney, Australia
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2000
- Sydney Retina Clinic
-
Sydney, New South Wales, Australie, 2135
- Sydney, Australia
-
-
-
-
-
Medellín, Colombie, 50016
- Medellin, Colombia
-
-
Antioquia
-
Medellín, Antioquia, Colombie, 50021
- Medellin, Colombia
-
-
Atlántico
-
Barranquilla, Atlántico, Colombie, 80002
- Barranquilla, Colombia
-
-
Columbia
-
Bogotá, Columbia, Colombie, 110231
- Bogota, Columbia
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombie, 760042
- Cali, Colombia
-
-
-
-
-
Osijek, Croatie, 31000
- Osijek, Croatia
-
-
-
-
-
Barcelona, Espagne, 08035
- Barcelona, Spain
-
Barcelona, Espagne, 08021
- Barcelona, Spain
-
Barcelona, Espagne, 08022
- Barcelona, Spain
-
Barcelona, Espagne, 08195
- Barcelona, Spain
-
Santiago de Compostela, Espagne, 15706
- Santiago de Compostela, Spain
-
Seville, Espagne, 41009
- Sevilla, Spain
-
Zaragoza, Espagne, 50009
- Zaragoza, Spain
-
-
Valencia
-
Burjassot, Valencia, Espagne, 46100
- Valencia, Spain
-
-
-
-
-
Créteil, France, 94010
- Creteil, France
-
Lyon, France, 69004
- Lyon, France
-
Marseille, France, 13008
- Marseille, France
-
Paris, France, 75006
- Paris, France
-
Paris, France, 75015
- Paris, France
-
Paris, France, 75019
- Paris, France
-
Saint-Cyr-sur-Loire, France, 37540
- Saint Cyr sur Loire, France
-
-
Cedex
-
Dijon, Cedex, France, 21079
- Cedex, France
-
-
-
-
-
Budapest, Hongrie, H-1062
- Budapest, Hungary
-
Budapest, Hongrie, H-1085
- Budapest, Hungary
-
Budapest, Hongrie, H-1106
- Budapest, Hungary
-
Budapest, Hongrie, H-1133
- Budapest, Hungry
-
Debrecen, Hongrie, H-4032
- Debrecen, Hungary
-
Pécs, Hongrie, H-7621
- Pecs, Hungary
-
Szeged, Hongrie, H-6720
- Szeged, Hungary
-
Zalaegerszeg, Hongrie, 8900
- Zalaegerszeg, Hungary
-
-
-
-
-
Be’er Ya‘aqov, Israël, 70300
- Beer Yakov, Israel
-
Haifa, Israël, 3436212
- Haifa, Israel
-
Jerusalem, Israël, 9112001
- Jerusalem, Israel
-
Petah Tikva, Israël, 49100
- Petah Tikva, Israel
-
Rehovot, Israël, 76100
- Rehovot, Israel
-
Tel Aviv, Israël, 6423906
- Tel Aviv, Israel
-
-
-
-
-
Bologna, Italie, 40138
- Bologna, Italy
-
Florence, Italie, 50139
- Firenze, Italy
-
Milan, Italie, 20122
- Milano, Italy
-
Milan, Italie, 20132
- Milano, Italy
-
Milan, Italie, 20157
- Milano, Italy
-
Roma, Italie, 00168
- Roma, Italy
-
Rome, Italie, 81.00133
- Rome, Italy
-
Udine, Italie, 33100
- Udine, Italy
-
-
-
-
-
Graz, L'Autriche, 8036
- Graz, Austria
-
Innsbruck, L'Autriche, 6020
- Innsbruck, Austria
-
Vienna, L'Autriche, 1090
- Vienna, Austria
-
Vienna, L'Autriche, 1140
- Vienna, Austria
-
-
-
-
-
Coimbra, Le Portugal, 3000-548
- Coimbra, Portugal
-
Coimbra, Le Portugal, 3030-163
- Coimbra, Portugal
-
Porto, Le Portugal, 4200-319
- Porto, Portugal
-
-
-
-
-
Riga, Lettonie, LV1002
- Riga, Latvia
-
Riga, Lettonie, LV1006
- Riga, Latvia
-
-
-
-
-
Bialystok, Pologne, 15-866
- Bialystok, Poland
-
Bydgoszcz, Pologne, 85-309
- Bydgoszcz, Poland
-
Bydgoszcz, Pologne, 85-631
- Bydgoszcz, Poland
-
Gdansk, Pologne, 80-809
- Gdansk, Poland
-
Katowice, Pologne, 40-594
- Katowice, Poland
-
Krakow, Pologne, 31-501
- Krakow, Poland
-
Olsztyn, Pologne, 10-424
- Olsztyn, Poland
-
Tarnowskie Góry, Pologne, 42-600
- Tarnowskie Gory, Poland
-
-
Gdansk
-
Gdansk, Gdansk, Pologne, 80-809
- Gdansk, Poland
-
-
-
-
PR
-
Arecibo, PR, Porto Rico, 00612
- Arecibo, PR
-
-
-
-
-
Bradford, Royaume-Uni, BD9 6RJ
- Bradford, United Kingdom
-
Bristol, Royaume-Uni, BS1 2LX
- Bristol, UK
-
Liverpool, Royaume-Uni, L7 8YA
- Liverpool, United Kingdom
-
Sunderland, Royaume-Uni, SR2 9HP
- Sunderland, United Kingdom
-
Wolverhampton, Royaume-Uni, WV10 0QP
- Wolverhamptom, United Kingdom
-
-
Middlesex
-
London, Middlesex, Royaume-Uni, NW10 7NS
- London, UK
-
-
UnitedKingdom
-
York, UnitedKingdom, Royaume-Uni, YO10 4DZ
- York, United Kingdom
-
-
-
-
-
Trebišov, Slovaquie, 075 01
- Trebisov, Slovakia
-
Trenčín, Slovaquie, 911 01
- Trencin, Slovakia
-
Žilina, Slovaquie, 012 07
- Zilina, Slovakia
-
-
-
-
-
Mladá Boleslav, Tchéquie, 293 01
- Mlada Boleslav, Czechia
-
Náchod, Tchéquie, 547 01
- Nachod, Czechia
-
Prague, Tchéquie, 1150/50
- Prague, Czechia
-
Prague, Tchéquie
- Prague, Czechia
-
-
-
-
Turkey
-
Ankara, Turkey, Turquie (Türkiye), 06230
- Ankara, Turkey
-
Ankara, Turkey, Turquie (Türkiye), 06490
- Ankara, Turkey
-
Balçova, Turkey, Turquie (Türkiye), 35330
- Balcova, Turkey
-
-
-
-
Arizona
-
Scottsdale, Arizona, États-Unis, 85255
- Scottsdale
-
-
Arkansas
-
Fayetteville, Arkansas, États-Unis, 72703
- Fayetteville, Arkansas
-
Springdale, Arkansas, États-Unis, 72764
- Springdale, Arkansas
-
-
California
-
Bakersfield, California, États-Unis, 93309
- Bakersfield, CA
-
Glendale, California, États-Unis, 91204
- Glendale, CA
-
Modesto, California, États-Unis, 95356
- Modesto, CA
-
Mountain View, California, États-Unis, 94040
- Mountain View, CA
-
Redlands, California, États-Unis, 92374
- Redlands, CA
-
Sacramento, California, États-Unis, 95825
- Sacramento, CA
-
Sacramento, California, États-Unis, 95841
- Sacramento, CA
-
Santa Ana, California, États-Unis, 92705
- Santa Ana
-
-
Colorado
-
Colorado Springs, Colorado, États-Unis, 80909
- Colorado Springs, CO
-
Denver, Colorado, États-Unis, 80210
- Denver, Colorado
-
-
Connecticut
-
Danbury, Connecticut, États-Unis, 06810
- Danbury, CT
-
Manchester, Connecticut, États-Unis, 06042
- Manchester, CT
-
Waterford, Connecticut, États-Unis, 06385
- Waterford,CT
-
-
Florida
-
Deerfield Beach, Florida, États-Unis, 33064
- Deerfield Beach, FL
-
Fort Lauderdale, Florida, États-Unis, 33308
- Fort Lauderdale, FL
-
Fort Myers, Florida, États-Unis, 33912
- Fort Myers,FL
-
Gainesville, Florida, États-Unis, 32607
- Gainesville, FL
-
Orlando, Florida, États-Unis, 32806
- Orlando, Florida
-
Plantation, Florida, États-Unis, 33324
- Plantation, FL
-
Sarasota, Florida, États-Unis, 34232
- Sarasota, FL
-
St. Petersburg, Florida, États-Unis, 33711
- Saint Petersburg, FL
-
Tallahassee, Florida, États-Unis, 32308
- Tallahassee, FL
-
Tampa, Florida, États-Unis, 33609-4614
- Tampa, FL
-
Tampa, Florida, États-Unis, 33617
- Tampa, FL
-
Winter Haven, Florida, États-Unis, 33880
- Winter Haven, FL
-
-
Illinois
-
Lemont, Illinois, États-Unis, 60439
- Lemont, IL
-
Springfield, Illinois, États-Unis, 62702
- Springfield, Illinois
-
-
Iowa
-
West Des Moines, Iowa, États-Unis, 50266
- West Des Moines, IA
-
-
Kansas
-
Lenexa, Kansas, États-Unis, 66215
- Lenexa, Kansas
-
Wichita, Kansas, États-Unis, 67214
- Wichita, Kansas
-
-
Maine
-
Portland, Maine, États-Unis, 04101
- Portland, Maine
-
-
Maryland
-
Hagerstown, Maryland, États-Unis, 21740
- Hagerstown, MD
-
-
Massachusetts
-
Springfield, Massachusetts, États-Unis, 01107
- Springfield,MA
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49546
- Grand Rapids, Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55435
- Minneapolis, MN
-
-
Mississippi
-
Madison, Mississippi, États-Unis, 39110
- Madison, MS
-
-
New Jersey
-
Bloomfield, New Jersey, États-Unis, 07003
- Bloomfield, NJ
-
Cherry Hill, New Jersey, États-Unis, 08034
- Cherry Hill, NJ
-
-
New York
-
Liverpool, New York, États-Unis, 13088
- Liverpool, NY
-
Oceanside, New York, États-Unis, 11572
- Oceanside, NY
-
Rochester, New York, États-Unis, 14620
- Rochester, NY
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 28803
- Asheville, NC
-
Hickory, North Carolina, États-Unis, 28602
- Hickory, NC
-
Wake Forest, North Carolina, États-Unis, 27587
- Wake Forest, MC
-
Winston-Salem, North Carolina, États-Unis, 27103
- Winston Salem, NC
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44122
- Cleveland, Ohio
-
Cleveland, Ohio, États-Unis, 44130
- Cleveland, OH
-
Youngstown, Ohio, États-Unis, 44505
- Youngstown, Ohio
-
-
Oklahoma
-
Edmond, Oklahoma, États-Unis, 73013
- Edmond, OK
-
-
Oregon
-
Portland, Oregon, États-Unis, 97221
- Portland, OR
-
Springfield, Oregon, États-Unis, 97477
- Springfield, Oregon
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, États-Unis, 18017
- Bethlehem, PA
-
Erie, Pennsylvania, États-Unis, 16507
- Erie, PA
-
-
South Carolina
-
Beaufort, South Carolina, États-Unis, 29902
- Beaufort, SC
-
Florence, South Carolina, États-Unis, 29501
- Florence, SC
-
Ladson, South Carolina, États-Unis, 29456
- Ladson, SC
-
West Columbia, South Carolina, États-Unis, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, États-Unis, 38138
- Germantown, TN
-
Hixson, Tennessee, États-Unis, 37343
- Hixson, Tennessee
-
Johnson City, Tennessee, États-Unis, 37604
- Johnson City, Tennessee
-
Knoxville, Tennessee, États-Unis, 37922
- Knoxville, TN
-
Nashville, Tennessee, États-Unis, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, États-Unis, 79606
- Abilene, TX
-
Amarillo, Texas, États-Unis, 79109
- Amarillo, TX
-
Amarillo, Texas, États-Unis, 79106
- Amarillo, TX
-
Arlington, Texas, États-Unis, 76012
- Arlington, TX
-
Austin, Texas, États-Unis, 78705
- Austin, TX
-
Beaumont, Texas, États-Unis, 77707
- Beaumont, TX
-
Bellaire, Texas, États-Unis, 77401
- Bellaire, TX
-
Dallas, Texas, États-Unis, 75231
- Dallas, TX
-
Fort Worth, Texas, États-Unis, 76104
- Fort Worth, TX
-
Katy, Texas, États-Unis, 77494
- Katy, TX
-
Plano, Texas, États-Unis, 75075
- Plano, TX
-
Round Rock, Texas, États-Unis, 78681
- Round Rock, TX
-
San Antonio, Texas, États-Unis, 78240
- San Antonio, TX
-
Schertz, Texas, États-Unis, 78154
- Schertz, Texas
-
The Woodlands, Texas, États-Unis, 77384
- The Woodlands, TX
-
Willow Park, Texas, États-Unis, 76087
- Willow Park, TX
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84107
- Salt Lake City, Utah
-
-
Virginia
-
Lynchburg, Virginia, États-Unis, 24502
- Lynchburg, VA
-
Richmond, Virginia, États-Unis, 23235
- Richmond, Virginia
-
-
Washington
-
Spokane, Washington, États-Unis, 99204
- Spokane, WA
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).
Exclusion Criteria:
-
Be pregnant or breastfeeding
-
History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
-
Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
-
Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
-
If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Remigromig Low Dose Treatment Arm
Remigromig Low Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Autres noms:
|
|
Expérimental: Remigromig High Dose Treatment Arm
Remigromig High Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Autres noms:
|
|
Comparateur actif: Ranibizumab Treatment Arm
Ranibizumab Treatment Arm |
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Délai: Baseline and Week 52
|
The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Baseline and Week 52
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Délai: Baseline and Week 52
|
The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented. |
Baseline and Week 52
|
|
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Délai: Baseline and Week 52
|
The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Time to Absence of Diabetic Macular Edema (DME)
Délai: Up to approximately Week 104
|
The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented. |
Up to approximately Week 104
|
|
Time to Gaining ≥15 ETDRS letters
Délai: Up to approximately Week 52
|
The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Up to approximately Week 52
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Délai: Up to approximately Week 24
|
The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented. |
Up to approximately Week 24
|
|
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Délai: Up to approximately Week 52
|
The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Délai: Baseline and Week 52
|
The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Délai: Up to approximately Week 52
|
The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Délai: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Délai: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Délai: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 104 Weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Charles Miller, MD PhD, EyeBiotech Ltd.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EYE-RES-102
- MK-3000-001 (Autre identifiant: MSD)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .